Stockscreener 앱 받기
0.35%
Amgen Inc 주식(AMGN)의 최신 뉴스
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
Here's Why Amgen (AMGN) is a Strong Momentum Stock - Zacks Investment Research
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
Amgen (AMGN) Laps the Stock Market: Here's Why - Zacks Investment Research
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Stock Market News for Oct 8, 2026 - Zacks Investment Research
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
Can Amgen (NASDAQ:AMGN) Win With Direct-to-Patient Access Programs? - Kalkine Media
3,524 Amgen Inc. $AMGN Shares Sold by Colton Groome Financial Advisors LLC - MarketBeat
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance UK
Amgen Inc. $AMGN Shares Purchased by MassMutual Private Wealth & Trust FSB - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Ferguson Wellman Capital Management Inc. - MarketBeat
2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC - MarketBeat
AMGEN INC. R (AMG.MU) Q2 FY2026 earnings call transcript - Yahoo Finance
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com - Investing.com India
Is AMGN Overvalued? DCF Says Worth $189 - GuruFocus
Amgen Inc Stock Futures,Dec-202 (SAMGN=F) Interactive Stock Chart - Yahoo! Finance Canada
Amgen Inc. $AMGN Shares Sold by CX Institutional - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock - benzinga.com
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Inc Investor Call At IASLC 2019 World Conference on Lung Cancer Transcript - GuruFocus
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know - TradingKey
Amgen Inc (AMGN) Shares Fall 3.4% -- GF Value Says Still Overval - GuruFocus
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
More Than Skin Deep: Understanding Discoid Lupus Erythematosus - Amgen
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win - Zacks Investment Research
Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight - GlobeNewswire Inc.
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial - insights.citeline.com
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities - GlobeNewswire Inc.
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody - Fierce Biotech
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors - GuruFocus
Amgen Inc. stock outperforms competitors on strong trading day - marketwatch.com
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen (NASDAQ:AMGN) Stock: Dazodalibep's Phase 3 Win Targets a Disease With No Approved Medicines - kalkine.ca
Amgen Inc Agencies, 2017 - OpenSecrets
Amgen (NASDAQ:AMGN) Reports Positive Dazodalibep Data in Sjogren's - Kalkine Media
AMGN Maintains Rating by Scotiabank -- Price Target Raised to $5 - GuruFocus
Scotiabank maintains Sector Outperform rating on Amgen, $500 price target - tradingview.com
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead - Yahoo Finance
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead - 24/7 Wall St.
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? - Yahoo Finance
0.76%
0.16%
자본화:
|
볼륨(24시간):